Company in its Board Meeting has approved financial results for period ended 31st march, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Godavari Drugs reported audited FY2026 results with revenue declining 6.7% to ₹10,580.81 lakhs from ₹11,335.01 lakhs in FY2025. Net profit fell 6.6% to ₹408.91 lakhs from ₹438.00 lakhs. The company completed a preferential allotment of 25.96 lakh equity shares in March 2026 raising ₹4,411.73 lakhs, increasing share capital to ₹1,012.74 lakhs. Operating cash flow dropped sharply to ₹73.36 lakhs from ₹1,119.60 lakhs, driven by a large ₹1,812.29 lakh increase in inventories. Statutory auditors issued an unmodified opinion with no qualifications. Related party transactions totaling ₹376.32 lakhs were disclosed, including director loans and remuneration.
Revenue and profit decline signals weakness in pharmaceutical ingredients business. Sharp drop in operating cash flow despite equity raise raises concerns about working capital management. Clean audit opinion provides some comfort to investors.